Is NCT06986174 recruiting in Boston, MA?

Yes, NCT06986174 is currently recruiting participants at its Boston, MA location. This waldenström macroglobulinemia clinical trial is actively enrolling qualified participants.

How do I join the waldenström macroglobulinemia clinical trial in Boston?

To join this clinical trial in Boston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Boston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Waldenström Macroglobulinemia Clinical Trial in Boston, MA

Who Can Participate

Inclusion Criteria

Age ≥18 years

ECOG performance status ≤2

Clinicopathological diagnosis of Waldenström Macroglobulinemia

Symptomatic disease meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenström macroglobulinemia. At least one of the following:

constitutional symptoms: recurrent fever, night sweats, fatigue or weight loss

progressive or symptomatic lymphadenopathy or splenomegaly

hemoglobin ≤10 g/dL

platelet count ≤100 k/uL

hyperviscosity syndrome

symptomatic peripheral neuropathy

systemic amyloidosis

renal insufficiency

symptomatic cryoglobulinemia

Serum IgM level ≥ 2 times the upper limit of normal

Participants must meet the following organ and marrow functions as defined below:

absolute neutrophil count ≥0.5 k/uL without growth factor within 7 days

platelet count ≥50 k/uL without platelet transfusion within 7 days

total bilirubin ≤1.5 times the upper limit of normal or ≤3 times the upper limit of normal with documented liver involvement, hemolysis or Gilbert's disease

AST (SGOT) and ALT (SGPT) ≤2.5 times the upper limit of normal or ≤5 times the upper limit of normal with documented liver involvement

Creatinine clearance ≥30 ml/min using Cockcroft/Gault equation

Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged)

At least 2 prior lines of treatment for Waldenström Macroglobulinemia. Participants must either be BTK inhibitor exposed or not be a candidate for BTK therapy.

Women of childbearing potential: Females of childbearing potential (FCBP) will be required to use two highly effective forms of contraception simultaneously or will remain abstinent from heterosexual intercourse during the following periods related to this study:

while participating in the study; and 2) for at least three months (90 days) after discontinuation from the study. FCBP must be referred to a qualified provider of contraceptive methods if needed.

Exclusion Criteria

Current history of uncontrolled HIV

Patients with a known history of HIV must have a viral load assessed for eligibility and must be on a stable antiretroviral regimen that can be administered concurrent with pacritinib.

Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below

Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (antiHBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before enrollment. Patients who are hepatitis B PCR positive will be excluded.

Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before enrollment. Patients who are hepatitis C RNA positive will be excluded.

Participants with chronic liver disease and hepatic impairment meeting Child-Pugh class B or C (Appendix B)

Participants who are pregnant, breast feeding, or planning to become pregnant while enrolled in this study or within 3 month after last study dose (2 weeks for breastfeeding)

Current CNS involvement by WM

Active alcohol or drug abuse

Concurrent administration of medications that are moderate or strong inhibitors or inducers of CYP3A within 14 days or 5 half-lives, whichever is shorter, prior to first dose of study drug.

Concurrent participation in another therapeutic clinical trial

History of another malignancy, except adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, localized prostate cancer, or other adequately treated cancer currently in complete remission

Prior or ongoing clinically significant illness, including active infections requiring antibiotics, of medical condition that, in the investigator's opinion, could affect the safety of the patient; alter the absorption, distribution, metabolism or excretion of the study drug; or impair the assessment of study results

Inability to swallow pills

Significant cardiovascular disease defined as:

Unstable angina, or

History of myocardial infarction within 6 months prior to planned start

Previously documented left ventricular ejection fraction (LVEF) by any method of ≤ 45% in the 12 months prior to planned start; assessment of LVEF via echocardiogram or multigated acquisition (MUGA) scan during screening should be performed in selected patients as medically indicated, or

Any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or

Uncontrolled or symptomatic arrhythmias

Prolonged QT Interval with baseline QTc \>480 msec using the Bazette formula

Ongoing, active infection.

Active bleeding requiring blood transfusion or other medical intervention. Participants requiring anticoagulation therapy are not excluded.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT06986174) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Waldenström Macroglobulinemia Treatment Options in Boston, MA

If you're searching for waldenström macroglobulinemia treatment options in Boston, MA, this clinical trial (NCT06986174) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced waldenström macroglobulinemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all waldenström macroglobulinemia clinical trials near you to find additional studies recruiting in your area.

Waldenström Macroglobulinemia Clinical Trial in Boston, MA

Expert Care in Boston

IRB Approved

No-Cost Care

Apply for This Boston Location

Why Participate?

Simple Process

About This Waldenström Macroglobulinemia Study in Boston